Paul Tudor Jones Immunovant, Inc. Transaction History

Tudor Investment Corp Et Al

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$30.27 - $43.79 $1.48 Million - $2.15 Million	49,055 Added 127.94%	87,397 $2.82 Million
Q4 2023 Feb 14, 2024	BUY	$31.31 - $44.19 $1.2 Million - $1.69 Million	38,342 New	38,342 $1.62 Million
Q2 2023 Aug 14, 2023	SELL	$14.2 - $23.75 $748,141 - $1.25 Million	-52,686 Reduced 78.61%	14,333 $271,000
Q1 2023 May 15, 2023	BUY	$15.27 - $19.72 $1.02 Million - $1.32 Million	67,019 New	67,019 $1.04 Million

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.